Pages that link to "Q33529398"
Jump to navigation
Jump to search
The following pages link to Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study (Q33529398):
Displaying 50 items.
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (Q22306358) (← links)
- The Role of Galectin-3 in the Kidneys (Q26752754) (← links)
- Clinical adoption of prognostic biomarkers: the case for heart failure (Q26863716) (← links)
- Cardiac biomarkers: new tools for heart failure management (Q26991726) (← links)
- Statins in heart failure: do we need another trial? (Q26998966) (← links)
- Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies (Q27002436) (← links)
- Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection (Q30405402) (← links)
- Network analysis of ChIP-Seq data reveals key genes in prostate cancer (Q30847259) (← links)
- Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study (Q33577541) (← links)
- Novel biomarkers for cardiovascular risk prediction (Q33615459) (← links)
- Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care (Q33658456) (← links)
- Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells (Q33863482) (← links)
- Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure (Q33912126) (← links)
- Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure (Q34102031) (← links)
- Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans (Q34122713) (← links)
- Plasma levels of alpha-1-antichymotrypsin are elevated in patients with chronic heart failure, but are of limited prognostic value. (Q34161212) (← links)
- Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). (Q34269132) (← links)
- Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair (Q34338521) (← links)
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction (Q34528187) (← links)
- Emerging biomarkers in heart failure and cardiac cachexia (Q34836097) (← links)
- Biomarkers in cardiology--part 1--in heart failure and specific cardiomyopathies (Q34914470) (← links)
- Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure (Q34997796) (← links)
- Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis (Q35070734) (← links)
- Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. (Q35109460) (← links)
- The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists (Q35191679) (← links)
- Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). (Q35206146) (← links)
- Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? (Q35286926) (← links)
- Soluble IgE receptors--elements of the IgE network (Q35491143) (← links)
- Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers (Q35562745) (← links)
- Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study (Q35680958) (← links)
- N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease (Q35689476) (← links)
- Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies (Q36003071) (← links)
- Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease (Q36015686) (← links)
- Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation (Q36052222) (← links)
- Plasma galectin 3 and heart failure risk in the Physicians' Health Study (Q36283028) (← links)
- Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community (Q36439679) (← links)
- Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. (Q36522700) (← links)
- Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction (Q36627699) (← links)
- Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure (Q36757833) (← links)
- Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation (Q36877769) (← links)
- Galectin 3 complements BNP in risk stratification in acute heart failure. (Q36917873) (← links)
- Elevated galectin-3 precedes the development of CKD (Q37119904) (← links)
- Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities (Q37125501) (← links)
- Serial galectin-3 and future cardiovascular disease in the general population (Q37580709) (← links)
- Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. (Q37595342) (← links)
- Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. (Q37662291) (← links)
- Novel biomarkers in human terminal heart failure and under mechanical circulatory support (Q37894731) (← links)
- Biomarkers: optimizing treatment guidance in heart failure (Q37903747) (← links)
- Biomarkers in advanced heart failure: diagnostic and therapeutic insights (Q37905948) (← links)
- Galectins in acute and chronic inflammation (Q37983646) (← links)